Treatment of streptozotocin-induced diabetes mellitus in mice by intra-bone marrow bone marrow transplantation plus portal vein injection of beta cells induced from bone marrow cells

International Journal of Hematology
M LiS Ikehara

Abstract

Curative therapy for diabetes mellitus mainly involves pancreas or islet transplantation to recruit insulin-producing cells. This approach is limited, however, because of both the shortage of donor organs and allograft rejection. Intra-bone marrow bone marrow transplantation (IBM-BMT) has recently been shown to be effective in inducing donor-specific tolerance in mice and rats without the use of immunosuppressants. After induction of diabetes in 15 C3H mice with streptozotocin, the mice received both allotransplants of bone marrow cells from C57BL/6 mice by IBM-BMT and injections via the portal vein of insulin-producing cells that were induced in vitro from stem cells derived from adult C57BL/6 bone marrow. We evaluated the expression of these cells by examining the expression of not only insulin but also the crucial transcription factors insulin I and insulin II. The diabetic mice were treated with IBM-BMT and precultured insulin-producing cells. Hyperglycemia was normalized by 5 days after the treatment and remained normal for more than 45 days. This strategy might be applicable to patients with type I diabetes mellitus.

References

Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S IkeharaT O Yoshida
Feb 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J S RubinS A Aaronson
Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·R YasumizuS Ikehara
Nov 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·S IkeharaH Kuzuya
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·R F PereiraD J Prockop
Jun 10, 1993·The New England Journal of Medicine·D M Nathan
Jul 17, 1998·The Journal of Clinical Investigation·T YamaokaM Itakura
Sep 15, 1999·Proceedings of the National Academy of Sciences of the United States of America·G C KopenD G Phinney
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·S Bonner-WeirJ J O'Neil
Jun 6, 2002·Proceedings of the National Academy of Sciences of the United States of America·Lijun YangAmmon B Peck
Nov 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yuichi HoriSeung K Kim
Jun 12, 2003·Annals of the New York Academy of Sciences·C M VerfaillieY Jiang
Jun 24, 2003·Nature Biotechnology·David HessMickie Bhatia
Jul 9, 2003·Archives of Histology and Cytology·Keiko Y HayashiShohei Yamashina
Feb 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Hideto KojimaLawrence Chan
Mar 23, 2004·Laboratory Investigation; a Journal of Technical Methods and Pathology·Seh-Hoon OhBryon E Petersen
Sep 7, 2004·Diabetologia·B G ToppD T Finegood
Apr 13, 2005·Biochemical and Biophysical Research Communications·Kyung Suk ChoiChan-Wha Kim
Sep 7, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Hiroyuki KanedaSusumu Ikehara

❮ Previous
Next ❯

Citations

Jul 3, 2008·Current Opinion in Endocrinology, Diabetes, and Obesity

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.